Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

Research output: Contribution to journalArticle

Bibtex

@article{e9cff083fb3b4300babb93129132f937,
title = "Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities",
abstract = "Background Patients with chromosome 5 abnormalities and high-risk myelodysplastic syndromes or acute myeloid leukemia have a poor outcome. We hypothesized that increasing doses of lenalidomide may benefit this group of patients by inhibiting the tumor clone, as assessed by fluorescence in situ hybridization for del(5q31). Design and Methods Twenty-eight patients at diagnosis or with relapsed disease and not eligible for standard therapy (16 with acute myeloid leukemia, 12 with intermediate-risk 2 or high-risk myelodysplastic syndrome) were enrolled in this prospective phase II multicenter trial and treated with lenalidomide up to 30 mg daily for 16 weeks. Three patients had isolated del(5q), six had del(5q) plus one additional aberration, 14 had del(5q) and a complex karyotype, four had monosomy 5, and one had del(5q) identified by fluorescence in situ hybridization only. Results Major and minor cytogenetic responses, assessed by fluorescence in situ hybridization, were achieved in 5/26 (19{\%}) and 2/26 (8{\%}) patients, respectively, who received one or more dose of lenalidomide, while two patients achieved only a bone marrow response. Nine of all 26 patients (35{\%}) and nine of the ten who completed the 16 weeks of trial responded to treatment. Using the International Working Group criteria for acute myeloid leukemia and myelodysplastic syndrome the overall response rate in treated patients with acute myeloid leukemia was 20{\%} (3/15), while that for patients with myelodysplastic syndrome was 36{\%} (4/11). Seven patients stopped therapy due to progressive disease and nine because of complications, most of which were disease-related. Response rates were similar in patients with isolated del(5q) and in those with additional aberrations. Interestingly, patients with TP53 mutations responded less well than those without mutations (2/13 versus 5/9, respectively; P = 0.047). No responses were observed among 11 cases with deleterious TP53 mutations. Conclusions Our data support a role for higher doses of lenalidomide in poor prognosis patients with myelodysplastic syndrome and acute myeloid leukemia with deletion 5q. (Clinicaltrials.gov identifier NCT00761449).",
keywords = "lenalidomide, myelodysplastic syndrome, acute myeloid leukemia, P53, mutation",
author = "Lars Mollgard and Leonie Saft and Treppendahl, {Marianne Bach} and Ingunn Dybedal and Norgaard, {Jan Maxwell} and Jan Astermark and Elisabeth Ejerblad and Hege Garelius and Dufva, {Inge Hogh} and Monika Jansson and Martin Jadersten and Lars Kjeldsen and Olle Linder and Lars Nilsson and Hanne Vestergaard and Anna Porwit and Kirsten Gronbaek and Lindberg, {Eva Hellstrom}",
year = "2011",
doi = "10.3324/haematol.2010.039669",
language = "English",
volume = "96",
pages = "963--971",
journal = "Haematologica-The Hematology Journal",
issn = "1592-8721",
publisher = "Ferrata Storti Foundation",
number = "7",

}